official recheck unresolved mirror
Official restriction rechecked; the historical mirror conflict stays open
The official label still does not recommend severe impairment or ESRD with or without dialysis. The RX mirror could not be reliably re-read in this pass.
What to reconcileRetain the historical discrepancy and the printed renal-measure limitation. Reproductive-potential restrictions remain separate.
1 source identities and dates
VIVJOA - oteseconazole capsulesDailyMed / Mycovia Pharmaceuticals, Inc. | Source revision: 4/2022
VIVJOA oral oteseconazole for eligible females who are not of reproductive potential; selected official renal recheck.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.7.
source scope and renal guidanceNew v6.8
Before use: Oxaprozin oral caplets (Daypro)
Do not treat 600 mg daily as permission to use an NSAID in advanced kidney disease.
What to reconcileFirst establish that use is justified despite the renal warning; then apply only the exact product-label instructions.
2 source identities and dates
Oxaprozin oral caplets (Daypro) - selected label sectionsPfizer / DAYPRO prescribing information | Source revision: 11/2024
DAYPRO 600 mg oral caplets. This selected renal summary is for adult osteoarthritis/rheumatoid arthritis use; pediatric weight-based dosing is not supplied here.
Read this stored source Oxaprozin oral caplets (Daypro) - RX mirror renal summaryGlobalRPh RX List / product-label mirror | Source revision: 11/2024
DAYPRO 600 mg oral caplets. This selected renal summary is for adult osteoarthritis/rheumatoid arthritis use; pediatric weight-based dosing is not supplied here.
Read this stored source Selected source reconciliation only; independent clinician adjudication pending. Added: v6.8.
formulation scope
OXTELLAR XR: adult initial reduction and dialysis formulation choice
The renal adjustment is an adult starting-dose/titration pathway; the dialysis instruction favors immediate release.
What to reconcileDo not convert the adult ER pathway into a pediatric or interchangeable-product table.
1 source identities and dates
GlobalRPh RX List - OXTELLAR XRGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Oxcarbazepine - OXTELLAR XR tablets; selected source sections only, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.9.
source scope and renal guidance
Before use: Pacritinib (VONJO)
A manufacturer document retrieved from a URL containing 2024-09 is actually revised July 2026. Its renal avoid-use restriction remains separate from newer hepatic dosing instructions.
What to reconcileRead the document revision, not the URL folder date. Do not apply the hepatic dose reduction as a renal workaround.
1 source identities and dates
Pacritinib - VONJO manufacturer prescribing informationSobi / VONJO manufacturer prescribing information | Source revision: 07/2026
Adults with specified myelofibrosis and platelets below 50 x 10^9/L; accelerated-approval indication.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.4.
formulation scope
ERZOFRI: product-specific initiation is not the SUSTENNA schedule
The retrieved RX and exact DailyMed renal passages agree on ERZOFRI initiation and monthly maintenance. A mirror plus its underlying label is one label family, not independent corroboration.
What to reconcileKeep ERZOFRI initiation, maintenance, switching and missed-dose instructions together; do not add a Day-8 injection from a different paliperidone product.
2 source identities and dates
GlobalRPh RX List - ERZOFRIGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adult ERZOFRI intramuscular extended-release suspension; not another paliperidone formulation.
Read this stored source Paliperidone palmitate - ERZOFRIDailyMed / Shandong Luye Pharmaceutical Co., Ltd. | Source revision: Prescribing information revised 03/2025.
Adult ERZOFRI injection; product-specific renal initiation and maintenance only.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.5.
population scope
HAFYERA: general renal and geriatric sections must both be read
The geriatric renal restriction is more restrictive than the general adult mild-impairment pathway. This distinction is present in both the RX mirror and official label, not merely one rendering.
What to reconcileDo not silently override the age-specific statement. Seek product-label/pharmacy or manufacturer clarification before applying a general adult pathway to an elderly patient with renal impairment.
2 source identities and dates
GlobalRPh RX List - INVEGA HAFYERAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adults; INVEGA HAFYERA six-month intramuscular suspension. Read the separate geriatric limitation before applying general adult guidance.
Read this stored source Paliperidone palmitate - INVEGA HAFYERA six-month injectionDailyMed / Janssen Pharmaceuticals, Inc. | Source revision: Prescribing information revised 01/2025.
Adults; INVEGA HAFYERA six-month intramuscular suspension. Read the separate geriatric limitation before applying general adult guidance.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.4.
source scope
SUSTENNA: the official renal subsection supplies additional maintenance detail
The retrieved RX renal subsection gives a usual maintenance dose but omits the adjustable range and maximum in the official label. An omission is not evidence of opposing dose recommendations.
What to reconcileUse the complete product-specific source; do not extrapolate maintenance limits from the oral or longer-interval products.
2 source identities and dates
GlobalRPh RX List - INVEGA SUSTENNAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adults; INVEGA SUSTENNA intramuscular monthly suspension. Not oral paliperidone or the longer-interval injections.
Read this stored source Paliperidone palmitate - INVEGA SUSTENNA monthly injectionDailyMed / Janssen Pharmaceuticals, Inc. | Source revision: Source revision date not established in selected retrieval.
Adults; INVEGA SUSTENNA intramuscular monthly suspension. Not oral paliperidone or the longer-interval injections.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.4.
formulation scope
TRINZA: renal eligibility does not supply a switching schedule
The selected renal passages require prior adjustment and stabilization on the one-month formulation. They do not establish immediate interchangeability among all paliperidone products.
What to reconcileVerify the complete transition and missed-dose instructions for this formulation before use.
2 source identities and dates
GlobalRPh RX List - INVEGA TRINZAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adults; INVEGA TRINZA intramuscular three-month suspension after appropriate prior paliperidone treatment.
Read this stored source Paliperidone palmitate - INVEGA TRINZA three-month injectionDailyMed / Janssen Pharmaceuticals, Inc. | Source revision: Source revision date not established in selected retrieval.
Adults; INVEGA TRINZA intramuscular three-month suspension after appropriate prior paliperidone treatment.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.4.
guideline difference
ZEMPLAR: label dosing does not make routine active-vitamin-D therapy appropriate
The capsule label provides dosing once treatment is chosen. KDIGO discourages routine active vitamin D in adults with nondialysis CKD G3a-G5, reserving it for selected G4-G5 severe progressive hyperparathyroidism. This is a treatment-selection qualification, not a conflicting dose calculation.
What to reconcileAssess trends and modifiable factors before choosing therapy; do not transfer this nondialysis qualification to all dialysis patients.
2 source identities and dates
GlobalRPh RX List - ZEMPLAR CAPSULESGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Paricalcitol - ZEMPLAR oral capsules, adult renal regimens; selected renal passages, not a complete prescribing monograph.
Read this stored source KDIGO CKD-MBD - active vitamin D treatment selectionKDIGO | Source revision: 2017 CKD-MBD guideline recommendations reproduced in the 2020 quick reference.
Adult nondialysis CKD G3a-G5 treatment selection; separate dialysis recommendation noted. Not a pediatric dosing protocol.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.0.
monitoring scope
VELTASSA: renal no-adjustment does not establish emergency use
The renal statement does not remove the delayed-onset limitation or medication-separation and magnesium precautions.
What to reconcileUse complete potassium management and interaction review; do not use the selected adult starting schedule as a pediatric default.
1 source identities and dates
GlobalRPh RX List - VELTASSAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Patiromer - VELTASSA oral suspension; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.0.
monitoring scope
VOTRIENT: no adjustment is qualified by severe-renal and toxicity gaps
The renal statement coexists with unstudied severe/dialysis groups and proteinuria-related stopping rules.
What to reconcileRetain proteinuria surveillance and the full nephrotic-syndrome instruction; do not expand the studied population.
1 source identities and dates
GlobalRPh RX List - VOTRIENTGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Pazopanib - VOTRIENT tablets; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.0.
formulation scope
EMPAVELI: PK observation is not unrestricted renal or cross-route permission
The selected PK passage gives no explicit renal range or dialysis schedule. EMPAVELI is the subcutaneous product, not intravitreal pegcetacoplan.
What to reconcileRetain infection precautions and formulation identity; do not invent a dialysis regimen.
1 source identities and dates
GlobalRPh RX List - EMPAVELIGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Pegcetacoplan - EMPAVELI subcutaneous infusion; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.0.
population scope
PEGASYS: adult renal reduction is not a pediatric protocol
The selected adult schedule includes a further toxicity-related reduction. Pediatric renal guidance is not established there.
What to reconcileKeep adult renal initiation, adverse-event modification and pediatric evidence limits distinct.
1 source identities and dates
GlobalRPh RX List - PEGASYSGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Peginterferon alfa-2a - PEGASYS subcutaneous injection; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.0.
evidence limit
SOMAVERT: not studied is not no adjustment
The renal statement describes an unstudied population, not a validated dosing recommendation.
What to reconcileKeep renal uncertainty visible and consult the complete product and specialist guidance.
1 source identities and dates
GlobalRPh RX List - SOMAVERTGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Pegvisomant - SOMAVERT subcutaneous injection; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.0.
baseline vs toxicity
Baseline PK findings do not overrule immune-nephritis holds
The baseline eGFR PK finding is distinct from treatment-emergent creatinine toxicity requiring withholding or permanent discontinuation.
What to reconcileGrade toxicity, identify alternative causes and follow the complete immune-event guidance. Do not keep treatment unchanged solely because renal PK is relatively unaffected.
1 source identities and dates
GlobalRPh RX List - KEYTRUDA IVGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Intravenous pembrolizumab; baseline PK and treatment-emergent immune nephritis are different questions.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.2.
dose table scope
PEMAZYRE: amount and cycle are separate decisions
The severe nondialysis reduction retains the indication-specific schedule. The intermittent-HD statement is a separate population, not a general ESRD instruction.
What to reconcileKeep the continuous or intermittent cycle attached to its indication; do not extrapolate the HD statement to PD or CRRT.
2 source identities and dates
GlobalRPh RX List - PEMAZYREGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Pemigatinib - PEMAZYRE tablets; selected renal passages, not a complete prescribing monograph.
Read this stored source PEMAZYRE - official severe-renal schedule checkDailyMed / Incyte Corporation | Source revision: Prescribing information revised June 2023.
PEMAZYRE - official severe-renal schedule check; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.0.